- $4.25m
- $13.92m
- $91.86m
- 15
- 85
- 11
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.13 | ||
| Price to Tang. Book | 5.85 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.04 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -34.64% | ||
| Return on Equity | -34.5% | ||
| Operating Margin | -15.64% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.27 | 0.53 | 10.12 | 91.86 | 99.31 | n/a | 595.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medigus is a Israel-based medical device company specializing in developing minimally invasive endosurgical tools and imaging solutions across medical and industrial applications. The Company developed a range of micro video cameras underr micro ScoutCam portfolio of products and the Medigus Ultrasonic Surgical Endostapler, or MUSE system endoscopic device for the treatment of gastroesophageal reflux disease (GERD)
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- December 9th, 1999
- Public Since
- February 27th, 2006
- No. of Shareholders
- 1
- No. of Employees
- 77
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 25,524,570
- Address
- 10 HaNechoshet Street, TEL AVIV-YAFO, 6971072
- Web
- https://medigus.com/
- Phone
- +972 86466880
- Auditors
- Brightman Almagor Zohar & Co
Upcoming Events for MDGS
Similar to MDGS
Accelerate Diagnostics
NASDAQ Capital Market
Acutus Medical
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
As of Today at 19:14 UTC, shares in Medigus are trading at $2.50. This share price information is delayed by 15 minutes.
Shares in Medigus last closed at $2.50 and the price had moved by -44.32% over the past 365 days. In terms of relative price strength the Medigus share price has underperformed the S&P500 Index by -55.03% over the past year.
There is no consensus recommendation for this security.
Medigus does not currently pay a dividend.
Medigus does not currently pay a dividend.
Medigus does not currently pay a dividend.
To buy shares in Medigus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.50, shares in Medigus had a market capitalisation of $4.25m.
Here are the trading details for Medigus:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MDGS
Based on an overall assessment of its quality, value and momentum Medigus is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medigus. Over the past six months, its share price has underperformed the S&P500 Index by -43.24%.
As of the last closing price of $2.50, shares in Medigus were trading -28.11% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Medigus PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Medigus' directors